Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Two patients with psoriasis grew extra hair after using certain psoriasis medications.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

New cytokine-targeted therapies show promise for treating alopecia areata.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Pharmacy care clinics can reduce some emergency visits by managing certain conditions and medication issues.

Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Bone broth may improve health and prevent diseases.

Baricitinib is effective and safe for treating severe alopecia areata.

PCOS causes hormonal issues and infertility, with treatment options including medication and lifestyle changes.

Minoxidil can help regrow hair in people with alopecia areata.

New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Oral Apremilast effectively treats alopecia areata in most patients.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

Acne vulgaris is a common skin condition that can cause low self-esteem and depression, and early treatment is important to prevent scarring.

Monitoring for adverse effects in clinical treatments is crucial.

Four patients with a type of rickets and hair loss had different mutations in their vitamin D receptor gene, causing it to not work properly.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.